Acetylcysteine (N-acetylcysteine — Paracetamol Overdose)
Brand names: Parvolex
Acetylcysteine (N-acetylcysteine) is the antidote for paracetamol overdose, given intravenously to prevent or limit hepatotoxicity.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
US labelling (FDA)
Reference — US labelling, may differ from UKPre-Treatment Assessment Following Acute Ingestion ( 2.1 ) : Obtain a plasma or serum sample to assay for acetaminophen concentration at least 4 hours after ingestion. If the time of acetaminophen ingestion is unknown: Administer a loading dose of acetylcysteine injection immediately. Obtain an acetaminophen concentration to determine need for continued treatment. If the acetaminophen concentration cannot be obtained (or is unavailable or uninterpretable) within the 8-hour time interval after acetaminophen ingestion or there is clinical evidence of acetaminophen toxicity: Administer a loading dose of acetylcysteine injection immediately and continue treatment for a total of three doses over …
Source: US FDA prescribing information (openFDA / DailyMed), label dated 2022-04-05. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.
Clinical monograph
How it works
It replenishes hepatic glutathione and provides sulfhydryl groups that detoxify the reactive paracetamol metabolite (NAPQI), protecting hepatocytes from injury.
Prescribing in practice
- Anaphylactoid reactions (flushing, urticaria, itch and bronchospasm) are common and are usually infusion-rate related — slow or pause the infusion and treat the reaction, then resume.
- It is most effective started early but is given later where the treatment protocol indicates, including in late presentation, staggered overdose or established liver injury.
- Treatment decisions follow the paracetamol treatment nomogram and timing, with Toxbase/NPIS advice for staggered or uncertain-timing ingestions.
Monitoring
Monitor for anaphylactoid reactions during the infusion, and track paracetamol level (where timing allows), liver function, INR, renal function and acid-base status to guide continuation and assess hepatotoxicity.
Counselling the patient
- Brief the team that infusion-related reactions are common, manageable by slowing or pausing the infusion, and not a true allergy that contraindicates the antidote.
- Reassure the patient that the reaction can be controlled and treatment continued.
- Follow the treatment nomogram and Toxbase/NPIS advice for ongoing management.
Evidence & guidelines
Established antidote for paracetamol poisoning (Toxbase/NPIS).
Reference: MHRA Parvolex SPC; NPIS TOXBASE; NICE CG16 (Self-harm); Bateman et al. Lancet 2014 (SNAP trial); MHRA 2012 simplified regimen; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.